Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Getinge AB (publ) (GETI-B.ST)
Gothenburg, SE
Getinge AB, founded in 1904 and headquartered in Gothenburg, Sweden, is a prominent global supplier of medical technology solutions. The company's extensive portfolio is designed for critical healthcare environments, including operating rooms, intensive care units, and sterile processing facilities. Its operations are divided into three core segments: Acute Care Therapies, Life Science, and Surgical Workflows. Getinge offers a comprehensive array of specialized equipment and systems. This encompasses advanced solutions for sterile processing and containment, such as sterilizers, washers, isolators, and automated logistic systems. For the life sciences sector, they provide bioreactors, bioprocess control systems, and associated analytics tools. Within acute care and surgical settings, their offerings range from anesthesia machines, specialized monitoring systems, and various disposables, to instruments for cardiac surgery (like beating heart stabilizers), mechanical ventilation products, and extracorporeal life support (ECMO) solutions. Additionally, Getinge provides infrastructure for operating rooms, including lighting, tables, modular systems, and integrated management tools, alongside products for cleaning, disinfection, packaging, and comprehensive sterile supply management. Their product line further extends to diverse catheters (thoracic, endovascular), endoscopic vessel harvesting systems, patient flow and transport solutions, and specialized devices for vascular and cardiothoracic surgery. The company distributes its broad range of products globally through its proprietary sales companies, as well as via agents and distributors, serving markets across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.72% | -4.12% | +3.43% | -6.43% | -11.66% | -12.75% | +2.62% | -24.81% | -35.20% | +8.94% | +730.13% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 5 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Devices: +11.2%+0.6% Q1'26: -10.5% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+37.9% ★ Q1'26: +33.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+5.3% Q1'26: +11.3% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+10.8% ★ Q1'26: +9.9% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+7.4% ★ Q1'26: +5.5% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.86× Q1'26: 2.25× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 10 Rev. Ana. 9 EPS Ana. |
Dec 2027 10 Rev. Ana. 9 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
30.24B
est: 30.07B (+0.6%)
|
29.76B
est: 29.84B (-0.3%)
|
22.50B
est: 22.44B (+0.2%)
|
24.17B
est: 24.14B (+0.1%)
|
26.56B
est: 26.58B (-0.1%)
|
29.82B
est: 29.84B (-0.1%)
|
27.05B
est: 27.16B (-0.4%)
|
28.29B
est: 28.26B (+0.1%)
|
31.83B
est: 33.33B (-4.5%)
|
34.76B
est: 34.18B (+1.7%)
|
34.97B
est: 35.22B (-0.7%)
|
34.87B
34.32B – 35.86B
-1.0% YoY
|
36.52B
36.14B – 37.84B
+4.7% YoY
|
38.16B
38.03B – 38.30B
+4.5% YoY
|
42.31B
41.76B – 43.68B
+10.9% YoY
|
| EBITDA |
3.41B
est: 5.93B (-42.5%)
|
3.26B
est: 5.88B (-44.6%)
|
3.42B
est: 4.42B (-22.8%)
|
1.60B
est: 4.76B (-66.3%)
|
4.53B
est: 5.24B (-13.5%)
|
6.46B
est: 5.88B (+9.8%)
|
6.15B
est: 5.36B (+14.9%)
|
5.73B
est: 5.57B (+2.8%)
|
5.93B
est: 6.24B (-5.0%)
|
5.31B
est: 6.40B (-17.1%)
|
5.85B
est: 6.59B (-11.3%)
|
6.53B
6.43B – 6.72B
-1.0% YoY
|
6.84B
6.77B – 7.09B
+4.7% YoY
|
7.15B
7.12B – 7.17B
+4.5% YoY
|
7.92B
7.82B – 8.18B
+10.9% YoY
|
| EBIT |
2.72B
est: 3.94B (-31.1%)
|
1.52B
est: 3.91B (-61.0%)
|
1.51B
est: 2.94B (-48.8%)
|
-206.00M
est: 3.16B (-106.5%)
|
2.38B
est: 3.48B (-31.6%)
|
4.78B
est: 3.91B (+22.2%)
|
4.34B
est: 3.56B (+21.9%)
|
3.68B
est: 3.70B (-0.7%)
|
3.81B
est: 4.02B (-5.2%)
|
2.89B
est: 4.12B (-30.0%)
|
3.79B
est: 4.25B (-10.8%)
|
4.21B
4.14B – 4.33B
-1.0% YoY
|
4.41B
4.36B – 4.56B
+4.7% YoY
|
4.60B
4.59B – 4.62B
+4.5% YoY
|
5.10B
5.04B – 5.27B
+10.9% YoY
|
| Net Income |
1.39B
est: 2.08B (-33.1%)
|
1.19B
est: 2.17B (-45.2%)
|
1.38B
est: 1.88B (-26.8%)
|
-967.00M
est: 681.14M (-242.0%)
|
1.22B
est: 1.80B (-32.0%)
|
3.24B
est: 3.61B (-10.3%)
|
2.97B
est: 3.38B (-12.0%)
|
2.49B
est: 3.00B (-16.9%)
|
2.41B
est: 2.58B (-6.7%)
|
1.64B
est: 2.70B (-39.4%)
|
2.26B
est: 3.11B (-27.4%)
|
3.11B
2.94B – 3.27B
-0.2% YoY
|
3.31B
3.18B – 3.80B
+6.7% YoY
|
3.74B
3.28B – 4.55B
+12.8% YoY
|
4.47B
4.40B – 4.66B
+19.8% YoY
|
| SGA |
9.91B
est: 8.81B (+12.5%)
|
9.61B
est: 8.74B (+10.0%)
|
7.63B
est: 6.57B (+16.1%)
|
8.29B
est: 7.07B (+17.3%)
|
8.85B
est: 7.79B (+13.7%)
|
8.78B
est: 8.74B (+0.5%)
|
7.93B
est: 7.96B (-0.4%)
|
8.39B
est: 8.28B (+1.3%)
|
9.68B
est: 9.61B (+0.7%)
|
9.59B
est: 9.86B (-2.7%)
|
9.53B
est: 10.16B (-6.2%)
|
10.06B
9.90B – 10.34B
-1.0% YoY
|
10.53B
10.42B – 10.91B
+4.7% YoY
|
11.01B
10.97B – 11.05B
+4.5% YoY
|
12.20B
12.04B – 12.60B
+10.9% YoY
|
| EPS |
5.50
est: 7.63 (-27.9%)
|
4.91
est: 7.97 (-38.4%)
|
5.49
est: 6.90 (-20.5%)
|
-3.55
est: 2.50 (-242.0%)
|
4.49
est: 6.59 (-31.9%)
|
11.89
est: 13.25 (-10.3%)
|
10.90
est: 12.39 (-12.0%)
|
9.15
est: 11.00 (-16.8%)
|
8.86
est: 9.49 (-6.6%)
|
6.01
est: 9.80 (-38.7%)
|
8.29
est: 11.28 (-26.5%)
|
11.41
10.80 – 12.00
+1.1% YoY
|
13.04
11.66 – 13.96
+14.3% YoY
|
14.47
12.05 – 16.71
+11.0% YoY
|
16.42
16.14 – 17.12
+13.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares STOXX Europe Small 200 UCITS ETF (DE) EXSE.DE | 0.62% | 4.26M | 0.20% |
| 2 | iShares OMX Stockholm Capped UCITS ETF OM3X.DE | 0.53% | 1.13M | 0.10% |
| 3 | Invesco STOXX Europe 600 Optimised Health Care UCITS ETF SC0T.DE | 0.31% | 41.7K | 0.20% |
| 4 | iShares MSCI Europe Small-Cap ETF IEUS | 0.30% | 523.9K | 0.41% |
| 5 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.29% | 9.85M | 0.30% |
| 6 | iShares STOXX Europe 600 Health Care UCITS ETF (DE) EXV4.DE | 0.24% | 1.98M | 0.46% |
| 7 | State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR Acc ZPRX.DE | 0.23% | 1.78M | 0.30% |
| 8 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.13% | 299.2K | 0.83% |
| 9 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.13% | 18.03M | 0.40% |
| 10 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.11% | 379.7K | 0.23% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mattias Perjos | Chief Executive Officer, President & Director | 59M | male |
| Alexandra Holland | Executive Vice President of Brand & Communications | — | female |
| Anna Romberg | Executive Vice President of Sustainability, Legal & Compliance | — | female |
| Carsten Blecker | Chief Commercial Officer | — | male |
| David Kordel | Head of Investor Relations | — | — |
| Elin Frostehav | President of Acute Care Therapies | — | female |
| Eric Honroth | President of Life Science | — | male |
| Magnus Lundback | Executive Vice President of Human Resources | — | male |
| Patricia A. Fitch | President of North America Region | — | female |
| Agneta Palmer | Chief Financial Officer | — | female |
| Stephane Le Roy | President of Surgical Workflows | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GETI-B.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
